샘플 요청 목록

 카트 문의
시장보고서
상품코드
1779929

세계의 당뇨병 관련 안과 치료 시장

Diabetes Associated Ophthalmic Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 383 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 당뇨병 관련 안과 치료 시장은 2030년까지 461억 달러에 도달

2024년에 333억 달러로 추정되는 세계의 당뇨병 관련 안과 치료 시장은 2024-2030년의 분석 기간에 CAGR 5.6%로 성장하며, 2030년에는 461억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 당뇨병성 안과 치료제는 CAGR 6.6%를 기록하며, 분석 기간 종료시에는 289억 달러에 달할 것으로 예측됩니다. 당뇨병 안과용 기기 부문의 성장률은 분석 기간 중 CAGR 4.0%로 추정됩니다.

미국 시장은 91억 달러로 추정, 중국은 CAGR 9.0%로 성장 예측

미국의 당뇨병 관련 안과 치료 시장은 2024년에 91억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 9.0%를 견인하며, 2030년까지 94억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.6%와 5.6%로 예측됩니다. 유럽에서는 독일이 CAGR 3.6%로 성장할 것으로 예측됩니다.

세계 당뇨병 관련 안과 치료 시장 - 주요 동향 및 촉진요인 정리

당뇨병과 관련된 시력 장애는 어떻게 응급의료 요구를 생성하는가?

당뇨병성 망막증, 당뇨병성 황반부종, 녹내장 등 당뇨병과 관련된 안과 질환은 전 세계에서 당뇨병 유병률이 증가함에 따라 관심이 높아지고 있습니다. 혈당이 조절되지 않으면 망막의 섬세한 혈관이 손상되어 시력저하가 진행되어 심한 경우 실명에 이르게 됩니다. 특히 고령화 및 도시화 사회에서의 2형 당뇨병 유병률 증가는 첨단 안과 치료에 대한 수요를 더욱 부추기고 있습니다. 레이저 광응고술과 같은 전통적인 치료법 외에도 항혈관내피성장인자(anti-VEGF) 주사, 코르티코스테로이드 임플란트 등 보다 혁신적인 치료법이 시행되고 있으며, 시력 유지에 있으며, 치료성적의 개선이 입증되고 있습니다. 빛간섭단층촬영(OCT), 안저촬영 등 영상 진단 기술의 보급으로 당뇨병성 안질환을 조기에 발견하고 보다 효과적으로 관리할 수 있게 되었습니다. 또한 당뇨병 안과 의료에 대한 인식과 정부의 구상이 높아짐에 따라 더 많은 환자들이 적시에 치료를 받으려는 경향이 높아져 시장을 주도하고 있습니다.

당뇨병 환자 안과 치료의 최신 기술 혁신은 무엇인가?

당뇨병 관련 안질환 치료법은 생물제제, 최소침습 수술 기술, 서방형 약물전달 시스템 등의 발전으로 변화하고 있습니다. 라니비주맙과 아플리버셉트와 같은 항VEGF 생물제제의 도입은 혈관 누출을 감소시키고 질병의 진행을 막음으로써 당뇨병성 황반부종 관리를 크게 개선했습니다. 또한 코르티코스테로이드 기반 안구내 임플란트는 적은 주사 횟수로 장기적인 완화를 가져오고 환자의 순응도를 향상시킬 수 있으며, 인기를 끌고 있습니다. 또 다른 유망 혁신 분야는 유전자 치료로, 표적 유전자의 변형을 통해 정상적인 망막 기능을 회복시키는 것을 목표로 하고 있습니다. 망막 보철물이나 줄기세포를 이용한 재생 치료의 개발도 중증 환자의 시력 회복을 위한 새로운 길을 열어가고 있습니다. 안과에서 인공지능(AI)의 등장은 치료 경로를 더욱 최적화하고, 특히 스크리닝과 조기 발견에 있으며, 임상 결과를 개선하고 있습니다. 제약회사와 의료기기 회사들이 연구 노력을 강화하는 가운데, 당뇨병 관련 안과 치료의 미래는 점점 더 유망 것으로 보입니다.

안과 의료 접근성 향상으로 인한 시장 혜택은?

당뇨병 안과 치료의 가장 큰 변화 중 하나는 정부의 헬스케어 구상, 보험 적용 범위 확대, 원격의료 기술 발전에 힘입어 치료 접근성이 향상되었습니다는 점입니다. AI를 활용한 진단 툴이 1차 진료 현장에 통합되면 당뇨망막병증의 조기 발견이 가능해져 전문 안과 센터의 부담을 줄일 수 있습니다. 또한 이동 안과 진료소 및 지역 사회 봉사 프로그램은 의료 서비스를 받지 못하는 사람들에게 검진 및 치료 서비스를 제공하는 데 중요한 역할을 하고 있습니다. 안과 시술 및 약물 치료에 대한 보상 정책의 확대는 더 많은 환자들이 적시에 치료를 받을 수 있도록 더욱 촉진하고 있습니다. 당뇨병 유병률이 빠르게 증가하고 있는 신흥 국가에서는 국제 협력과 민관 파트너십을 통해 첨단 안과 치료 접근성이 향상되고 있습니다. 또한 비용 효율적인 항 VEGF 치료용 바이오시밀러의 개발로 치료비용이 절감되어 최첨단 치료법이 보다 널리 보급될 수 있을 것으로 기대되고 있습니다. 이러한 접근성 향상은 당뇨병 환자의 예방 가능한 실명을 억제하는 데 매우 중요한 역할을 하고 있습니다.

당뇨병 관련 안과 치료 시장의 주요 성장 촉진요인은?

당뇨병 관련 안과 치료 시장의 성장은 전 세계 당뇨병 부담 증가, 생물제제 채택 확대, 조기 진단 기술 발전 등 여러 요인에 의해 주도되고 있습니다. 당뇨병성 안질환 발병 위험이 높은 노인 인구 증가는 시장 확대에 크게 기여하고 있습니다. 서방형 임플란트 및 유전자 치료와 같은 약물전달의 혁신은 환자의 순응도와 임상적 효과를 향상시켜 새로운 치료법에 대한 수요를 더욱 증가시키고 있습니다. 또한 안과에서 AI의 도입이 진행됨에 따라 조기 발견율이 향상되어 보다 적극적인 치료 접근이 가능해졌습니다. 또한 안과 의료 접근성 향상을 위한 정부 주도의 인식 개선 프로그램 및 정책 개혁이 시장 성장에 중요한 역할을 하고 있습니다. 원격 안과 서비스의 확대와 모바일 진단 플랫폼의 보급은 특히 농촌과 저소득 지역의 의료 격차를 해소하고 있습니다. 또한 제약사들의 안과 연구개발에 대한 투자 확대와 바이오시밀러 경쟁의 부상으로 첨단 치료제의 가격이 더욱 저렴해져 시장 확대에 박차를 가하고 있습니다. 지속적인 기술 혁신과 환자들의 인식이 높아짐에 따라 당뇨병 관련 안과 치료 시장은 향후 수년간 지속적인 성장을 이룰 것으로 예측됩니다.

부문

유형(당뇨병 안과 치료제, 당뇨병 안과 치료 기기), 용도(당뇨망막병증 용도, 안구건조증 용도, 녹내장 용도, 눈 알레르기·감염증 용도, 기타 용도), 최종 용도(병원 최종 용도, 안과 센터 최종 용도, 외래 센터 최종 용도, 기타 최종 용도)

조사 대상 기업의 예

  • Alcon Management S. A.
  • American Academy of Ophthalmology
  • Bausch+Lomb Corp.
  • Bausch Health Companies Inc.
  • Carl Zeiss Meditec AG
  • Eyenuk, Inc.
  • F. Hoffmann-La Roche Ltd.
  • IRIDEX Corporation
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.07

Global Diabetes Associated Ophthalmic Treatment Market to Reach US$46.1 Billion by 2030

The global market for Diabetes Associated Ophthalmic Treatment estimated at US$33.3 Billion in the year 2024, is expected to reach US$46.1 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Diabetic Ophthalmic Drugs, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$28.9 Billion by the end of the analysis period. Growth in the Diabetic Ophthalmic Devices segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.1 Billion While China is Forecast to Grow at 9.0% CAGR

The Diabetes Associated Ophthalmic Treatment market in the U.S. is estimated at US$9.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.4 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Diabetes Associated Ophthalmic Treatment Market - Key Trends & Drivers Summarized

How Is Diabetes-Linked Vision Impairment Creating Urgent Medical Needs?

Diabetes-associated ophthalmic conditions, including diabetic retinopathy, diabetic macular edema, and glaucoma, have become a growing concern due to the rising global prevalence of diabetes. Uncontrolled blood sugar levels damage the delicate blood vessels in the retina, leading to progressive vision loss and, in severe cases, blindness. The increasing incidence of type 2 diabetes, particularly in aging populations and urbanizing societies, has fueled the demand for advanced ophthalmic treatments. Conventional treatment approaches, such as laser photocoagulation, are now being supplemented by more innovative therapies, including anti-vascular endothelial growth factor (anti-VEGF) injections and corticosteroid implants, which have demonstrated improved outcomes in preserving vision. The growing accessibility of diagnostic imaging technologies, such as optical coherence tomography (OCT) and fundus photography, is enabling early detection and more effective management of diabetic eye diseases. Furthermore, with increasing awareness and government initiatives focusing on diabetic eye care, more patients are seeking timely treatment, driving the market forward.

What Are the Latest Innovations in Ophthalmic Treatments for Diabetic Patients?

The treatment landscape for diabetes-related eye diseases is undergoing a transformation, with advancements in biologics, minimally invasive surgical techniques, and sustained-release drug delivery systems. The introduction of anti-VEGF biologics, such as ranibizumab and aflibercept, has significantly improved the management of diabetic macular edema by reducing vascular leakage and halting disease progression. Additionally, corticosteroid-based intraocular implants are gaining popularity due to their ability to provide long-term relief with fewer injections, thereby improving patient compliance. Another promising area of innovation is gene therapy, which aims to restore normal retinal function through targeted genetic modifications. The development of retinal prosthetics and regenerative therapies, including stem cell-based interventions, is also opening new avenues for vision restoration in severe cases. The emergence of artificial intelligence (AI) in ophthalmology, particularly in screening and early detection, is further optimizing treatment pathways and improving clinical outcomes. With pharmaceutical and medical device companies intensifying research efforts, the future of diabetes-associated ophthalmic treatment looks increasingly promising.

How Is the Market Benefiting from Increased Accessibility to Eye Care?

One of the major shifts in diabetic eye care is the increased accessibility to treatment, driven by government healthcare initiatives, insurance coverage expansions, and technological advancements in telemedicine. The integration of AI-powered diagnostic tools into primary care settings allows for early identification of diabetic retinopathy, reducing the burden on specialized ophthalmology centers. Additionally, mobile eye care units and community outreach programs are playing a crucial role in bringing screening and treatment services to underserved populations. The expansion of reimbursement policies for ophthalmic procedures and drug therapies is further encouraging more patients to seek timely intervention. In emerging economies, where diabetes prevalence is rising rapidly, international collaborations and public-private partnerships are enhancing access to advanced ophthalmic treatments. Furthermore, the development of cost-effective biosimilars for anti-VEGF therapies is expected to reduce treatment costs, making cutting-edge care more widely available. These improvements in accessibility are playing a pivotal role in curbing preventable blindness among diabetic populations.

What Are the Key Growth Drivers of the Diabetes-Associated Ophthalmic Treatment Market?

The growth in the diabetes-associated ophthalmic treatment market is driven by several factors, including the rising global diabetes burden, increasing adoption of biologic therapies, and advancements in early diagnostic technologies. The growing geriatric population, which is at a higher risk of developing diabetic eye diseases, is significantly contributing to market expansion. Innovations in drug delivery, such as sustained-release implants and gene therapy, are improving patient adherence and clinical efficacy, further boosting demand for novel treatments. The increasing deployment of AI in ophthalmology is also enhancing early detection rates, leading to more proactive treatment approaches. Additionally, government-led awareness programs and policy reforms aimed at improving eye care accessibility are playing a crucial role in market growth. The expansion of teleophthalmology services and the proliferation of mobile diagnostic platforms are bridging healthcare gaps, particularly in rural and low-income regions. Moreover, the growing investments by pharmaceutical companies in ophthalmic R&D and the rise of biosimilar competition are making advanced treatments more affordable, fueling further market expansion. With continuous innovation and increasing patient awareness, the diabetes-associated ophthalmic treatment market is poised for sustained growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Diabetes Associated Ophthalmic Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Diabetic Ophthalmic Drugs, Diabetic Ophthalmic Devices); Application (Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy and Infection Application, Other Applications); End-Use (Hospitals End-Use, Ophthalmic Centers End-Use, Ambulatory Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Alcon Management S. A.
  • American Academy of Ophthalmology
  • Bausch + Lomb Corp.
  • Bausch Health Companies Inc.
  • Carl Zeiss Meditec AG
  • Eyenuk, Inc.
  • F. Hoffmann-La Roche Ltd.
  • IRIDEX Corporation
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Diabetes Associated Ophthalmic Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Diabetes Throws the Spotlight on Ophthalmic Complications and Treatment Demand
    • Increased Screening and Early Diagnosis Spur Demand for Therapeutics Addressing Diabetic Retinopathy and Macular Edema
    • Growth in Anti-VEGF Therapy Adoption Strengthens the Business Case for Intravitreal Injections and Specialty Drugs
    • Expansion of Retinal Imaging and OCT Technology Enhances Precision in Monitoring Disease Progression
    • Digital Health and AI-Based Diagnostic Tools Accelerate Personalized Care in Diabetic Eye Disease Management
    • Integration of Teleophthalmology in Rural and Underserved Areas Improves Access to Retinal Screenings
    • Growing Use of Combination Therapies and Sustained-Release Implants Enhances Treatment Efficacy and Compliance
    • Reimbursement Policies and National Health Guidelines Drive Uptake of Retinopathy Treatments in Public Healthcare
    • Development of Non-Invasive Delivery Methods and Oral Agents Represents Next Frontier in Treatment Innovation
    • Ongoing Research in Neuroprotective and Anti-Inflammatory Agents Expands the Pipeline Beyond Vascular Targets
    • Patient Education and Awareness Campaigns Support Early Intervention and Regular Eye Exams
    • Rising Geriatric and Type 2 Diabetes Populations Sustain Long-Term Growth in Ophthalmic Interventions
    • Emerging Markets With High Diabetic Burden Offer Substantial Untapped Opportunities for Ophthalmic Drug Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Diabetes Associated Ophthalmic Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Diabetes Associated Ophthalmic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Diabetic Ophthalmic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Diabetic Ophthalmic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Diabetic Ophthalmic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Diabetic Ophthalmic Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Diabetic Ophthalmic Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Diabetic Ophthalmic Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Ambulatory Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Ambulatory Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Ambulatory Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Ophthalmic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Ophthalmic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Ophthalmic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Diabetic Retinopathy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Diabetic Retinopathy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Diabetic Retinopathy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Dry Eye Syndrome Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Dry Eye Syndrome Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Dry Eye Syndrome Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Glaucoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Glaucoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Glaucoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Eye Allergy & Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Eye Allergy & Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Eye Allergy & Infection Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Diabetes Associated Ophthalmic Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제